Biogen and Neomorph collaborate to develop molecular glue degraders for treating Alzheimer's and other diseases. The partnership aims to utilize Neomorph's platform for discovering small molecule therapeutic degraders, with Biogen leading clinical development and commercialization efforts.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing